MAYNE PHARMA GROUP LIMITED — Capital/Financing Update 2014

Feb 11, 2014

==> picture [104 x 96] intentionally omitted <==

MARKET RELEASE

12 February 2014

Mayne Pharma Group Limited

TRADING HALT

The securities of Mayne Pharma Group Limited (the “Company”) will be placed in Trading Halt Session State at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in Trading Halt Session State until the earlier of the commencement of normal trading on Thursday 13 February 2014 or when the announcement is released to the market.

Security Code: MYX

Dean Litis Principal Adviser Listings Compliance (Melbourne)

12 February 2014

The Manager Company Notices Section ASX Limited Level 45, South Tower, Rialto Towers 525 Collins Street MELBOURNE VIC 3000

Via E-Lodgement

Dear Sir/Madam

Mayne Pharma Group Limited – Request for Trading Halt

The directors of Mayne Pharma Group Limited ACN 115 832 963 (ASX: MYX) ( Mayne Pharma ) request a trading halt from the commencement of trading on 12 February 2014 at which time Mayne Pharma proposes to announce an institutional placement in order to fund an acquisition.

For the purposes of ASX Listing Rule 17.1, Mayne Pharma provides the following further information:

• (a) Mayne Pharma expects that the trading halt remain in place until the commencement of trading on 13 February 2014, unless, before that time, Mayne Pharma requests that the trading halt be lifted; and

• (b) Mayne Pharma is not aware of any reason why the trading halt should not be granted.

If you have any queries, please do not hesitate to contact the writer.

Yours faithfully, Mayne Pharma Group Limited

==> picture [202 x 45] intentionally omitted <==

Mark Cansdale Group CFO and Company Secretary

==> picture [581 x 69] intentionally omitted <==